Disease Management Will Yield More Savings In Medicare Than Private Plans, CMS Says
This article was originally published in The Pink Sheet Daily
Medicare beneficiaries offer a more stable population with a greater number of chronic diseases than those in private plans, CMS’ Guterman says. Current expectations about possible returns on investment from disease management programs are too high, Disease Management Purchasing Consortium says.
You may also be interested in...
PBMI Prescription Drug Utilization Conference attendees express caution about the motives of pharmaceutical manufacturer-sponsored disease management programs. Preliminary results from PBMI’s 2005 benefit design report found that a lower percentage of employers are using disease management programs.
HHS selects nine organizations to coordinate care for 180,000 Medicare beneficiaries with congestive heart failure, complex diabetes and chronic obstructive pulmonary disease. The programs will be evaluated through randomized controlled trials.
While studies show such programs improve control of diseases, the net effect on health costs is not clear, a Congressional Budget Office report says. Translating successful disease management results to the Medicare population could be difficult, the report notes.